Equities research analysts at The Goldman Sachs Group started coverage on shares of Privia Health Group (NASDAQ:PRVA – Get Rating) in a research report issued to clients and investors on Friday, The Fly reports. The brokerage set a "buy" rating and a $32.00 price target on the stock. The Goldman Sachs Group's price target would indicate a potential upside of 23.27% from the stock's previous close.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus began coverage on shares of Privia Health Group in a research report on Thursday, December 8th. They set a "buy" rating and a $28.00 price target for the company. SVB Leerink decreased their price target on shares of Privia Health Group from $46.00 to $39.00 and set an "outperform" rating for the company in a research report on Friday, November 11th. UBS Group started coverage on shares of Privia Health Group in a research report on Thursday, December 8th. They set a "buy" rating and a $30.00 price objective for the company. Canaccord Genuity Group decreased their price objective on shares of Privia Health Group from $50.00 to $43.00 and set a "buy" rating for the company in a research report on Friday, November 11th. Finally, Truist Financial cut their price target on shares of Privia Health Group to $41.00 in a research note on Thursday, November 17th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Privia Health Group currently has a consensus rating of "Buy" and an average target price of $38.93.

Privia Health Group Stock Down 6.3 %

Shares of NASDAQ:PRVA opened at $25.96 on Friday. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -72.11 and a beta of 0.81. Privia Health Group has a 52 week low of $17.99 and a 52 week high of $44.64. The firm has a 50 day moving average of $24.15 and a 200 day moving average of $30.99.

Insider Buying and Selling at Privia Health Group

In other news, Director William M. Sullivan sold 18,153 shares of the firm's stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $27.56, for a total transaction of $500,296.68. Following the completion of the transaction, the director now owns 6,172,493 shares in the company, valued at approximately $170,113,907.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Privia Health Group news, Director William M. Sullivan sold 18,153 shares of the firm's stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $27.56, for a total value of $500,296.68. Following the completion of the transaction, the director now directly owns 6,172,493 shares in the company, valued at $170,113,907.08. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director William M. Sullivan sold 12,115 shares of the firm's stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $21.24, for a total transaction of $257,322.60. Following the sale, the director now owns 5,832,968 shares of the company's stock, valued at $123,892,240.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,583,757 shares of company stock valued at $81,067,912. Company insiders own 57.60% of the company's stock.

Hedge Funds Weigh In On Privia Health Group

A number of institutional investors have recently modified their holdings of the company. ProShare Advisors LLC acquired a new stake in shares of Privia Health Group in the first quarter worth $210,000. JPMorgan Chase & Co. boosted its stake in Privia Health Group by 60.3% during the first quarter. JPMorgan Chase & Co. now owns 33,839 shares of the company's stock worth $905,000 after buying an additional 12,732 shares in the last quarter. US Bancorp DE boosted its stake in shares of Privia Health Group by 8.8% in the 1st quarter. US Bancorp DE now owns 13,923 shares of the company's stock valued at $372,000 after purchasing an additional 1,131 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Privia Health Group by 200.9% in the 1st quarter. MetLife Investment Management LLC now owns 23,742 shares of the company's stock valued at $635,000 after purchasing an additional 15,852 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Privia Health Group by 124.7% in the 1st quarter. Rhumbline Advisers now owns 36,873 shares of the company's stock valued at $986,000 after purchasing an additional 20,464 shares in the last quarter. Institutional investors own 66.83% of the company's stock.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Featured Articles

• Get a free copy of the StockNews.com research report on Privia Health Group (PRVA)
• MarketBeat Week in Review – 1/30 – 2/3
• Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
• Zimmer Biomet Beats on Earnings, Growth May be Priced In
• AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
• Ford Stock Going Forward After Big Earnings Flop

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.